Erratum. Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90–97

To comply with a new (January 2020) legal interpretation of the Data Use Agreement between the U.S. Food and Drug Administration’s Sentinel Initiative and the Centers for Medicare & Medicaid Services, the authors have made changes to the presentation of data in this article and the online supplementary material by 1) masking cells with small numbers, 2) masking certain cells that could be used to derive the cells with small numbers, 3) adding an explanatory note in tables, and 4) restricting analyses of diabetic ketoacidosis (DKA) rates to patients age ≥25 years. The following tables and figures are affected by these revisions:

Table 1

Figure 2

Figure 3

Supplementary Tables 1, 2, 3, and 4

Supplementary Figure 2

In addition, the following explanation was added under “Statistical Analysis” (Research Design and Methods section):

“Analyses of DKA rates were conducted among patients age ≥25 years due to few DKA events being observed among younger patients and a requirement by one of the data partners that cell sizes of 1 to 10 events not be displayed.”

Data presented in the text under “DKA During Follow-up” (Results section) were revised to reflect the age-group restriction.

The online version of the article (https://doi.org/10.2337/dc19-1481) has been updated, and revised supplementary material has been posted at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc19-1481/-/DC1.

• © 2020 by the American Diabetes Association